Cancer Clinical Trial -IDEAYA Biosciences- IDE397-001

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Drug

IDE397, Docetaxel, Paclitaxel, Gemcitabine, Nab paclitaxel, Pemetrexed

Phase

Phase I

Condition

Breast, Cholangiocarcinoma, Esophageal, Head and Neck, Melanoma, Mesothelioma, Non- Small Cell Lung, Pancreatic, Renal, Urothelial

Keywords

MAT2A | 9p21 | CDKN2A | PRMT5 | MTAP delectation | CDKN2A delectation